Product Name: Fes (711-720) pY713+pS716
Product Number: PE-04AFT90
| Size: | 200 µg | Price: | 66.00 | |
| 1 mg | $US | 133.00 | ||
| 5 mg | 313.00 |
Peptide Name: Fes (711-720) pY713+pS716
Product Use: Services as a blocking peptide for use with the FES-pY713+pS716 rabbit polyclonal antibody (Cat. No.: AB-PK633) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y713 and S716 phosphorylation stimulate phosphotransferase activity, and regulates cell differentiation, cell growth and molecular association, including inducing interaction with Fes.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: GV-pY-AA-pS-GGSL
Peptide Modifications N Terminus: Free amino
Product Use: Services as a blocking peptide for use with the FES-pY713+pS716 rabbit polyclonal antibody (Cat. No.: AB-PK633) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y713 and S716 phosphorylation stimulate phosphotransferase activity, and regulates cell differentiation, cell growth and molecular association, including inducing interaction with Fes.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: GV-pY-AA-pS-GGSL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1215.11 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Fes - pY713+pS716 phosphosite-specific antibody (Cat. No.: AB-PK633)
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1215.11 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Fes - pY713+pS716 phosphosite-specific antibody (Cat. No.: AB-PK633)
Scientific Background: Fes is a protein-tyrosine kinase of the TK group and Fer family. It functions downstream of membrane bound receptors and is involved in the regulation of the actin cytoskeleton, microtubule assembly, cell adhesion, and cell spreading. Additionally, Fes plays a role in the degranulation of mast cells and acts downstream of the FCER1 receptor and the mast/stem cell growth factor receptor Kit. In addition, Fes is involved in the regulation of cell differentiation as well as in the promotion of neurite growth in response to nerve growth factor (NGF) signalling. Known targets of the Fes protein include BCR, HCLS1/HS1, PECAM1, STAT3, and TRIM28. Phosphorylation of Y713 increases phosphotransferase activity and interaction with Fes. Fes has been demonstrated to be an oncoprotein in several human cancer types, potentially due to abnormal activation of the kinase catalytic function. It was originally identified as an oncoprotein from avian retroviral (Fps in Fujinami sarcoma virus) and cat retroviral (Fes in feline sarcoma virus) studies. Interestingly, Fes has also been shown to act as a tumour-suppressor protein in some human cancer types. For example, reduced or absent expression of the Fes protein is observed in colon cancer specimens and the ectopic expression of Fes in colon cancer cell lines results in the suppression of anchorage-independent cell growth, indicating a tumour suppressing role for the Fes protein. In contrast, Fes expression is significantly elevated in prostate cancer specimens and is thought to actively promote cell growth in renal carcinoma cell lines. In animal studies, mice lacking Fes expression displayed deficits in hematopoiesis and had significantly reduced numbers of circulating mature myeloid cells and immature myeloid precursors, indicating a oncogenic role for the Fes protein in this cancer.
© Kinexus Bioinformatics Corporation 2017